Open menu

Nanotechnology General News

The latest news from academia, regulators
research labs and other things of interest

Posted: September 7, 2010

Coriolis PharmaService Chooses NanoSight to Study the Aggregation of Protein Drugs and Vaccines

(Nanowerk News) Munich-based company Coriolis PharmaServices GmbH is using NanoSight's LM-20 nanoparticle characterization system to investigate the aggregation behaviour of protein drugs and vaccines.
Coriolis is a contract research organization for the formulation and analytics of pharmaceutical proteins and vaccines for their customers from national and international pharmaceutical companies. A special focus during formulation development is set on the characterization of subvisible particles and aggregation. The main application requirement for the NanoSight system is to measure the number and the size distribution of aggregates in pharmaceutical protein formulations and of vaccines, e.g. virus-like particles. Protein aggregation is a major stability issue and can result in reduced biological activity and enhanced immunogenicity of the product. Therefore, it is important to analyze the aggregation behaviour of pharmaceutical proteins and develop methods and formulations that avoid aggregation already at the beginning of formulation development.
The NanoSight LM 20 system in use at Coriolis PharmaServices
The NanoSight LM 20 system in use at Coriolis PharmaServices.
Coriolis uses a variety of instrumental techniques to quantify and size aggregates, depending on the size range of interest. Dynamic light scattering is ideal to analyze monodisperse systems, e.g. 5-20 nm range, but once the aggregates start to form and grow (in the hundreds of nm range), nanoparticle tracking analysis (NTA) from NanoSight gives a real distribution picture. For samples in the Ám range, microflow imaging (MFI) and light obscuration are used.
In contrast to DLS, NTA works well with polydisperse samples giving an estimation of the total concentration of particles and the possibility to distinguish different size populations, e.g. 60 and 100 nm particles. This is not possible by DLS due to the poor resolution.
Speaking at the recent National Biotech Conference 2010 in San Francisco, the Coriolis team under Dr Michael Wiggenhorn reported that to achieve a comprehensive characterization of nanoscale particulates in protein formulations, it is important to combine techniques that operate in that range. However, the ability of NTA to provide a real-time image of samples permits the analysis of potentially occurring difficulties during the measurement which is not possible using DLS.
To learn more about nanoparticle characterization using Nanoparticle Tracking Analysis, NTA, please visit the company website (www.nanosight.com) and register for the latest issue of NanoTrail, the company's electronic newsletter. For more about Coriolis, please see their website.
About NanoSight
NanoSight Limited, of Salisbury, UK, provides unique nanoparticle characterization technology. "Nanoparticle Tracking Analysis" (NTA) detects and visualizes populations of nanoparticles in liquids down to 10nm (material dependent) and measures the size of each particle from direct observations of diffusion. This particle-by-particle methodology goes beyond traditional light scattering techniques such as Dynamic Light Scattering (DLS), or Photon Correlation Spectroscopy (PCS), in providing high-resolution particle size distributions. Additionally NanoSight measures concentration and validates all data with video of particles moving under Brownian motion.
This characterization information is highly informative in understanding the more complex suspensions in biological systems, hence its wide application in development of drug delivery systems, viral vaccines, the study of toxicology of nanoparticles and their environmental fate and in biomarker detection. This real-time data also provides insight into the kinetics of protein aggregation and other time-dependent phenomena in a quantitative manner, at deeply sub-micron sizes.
NanoSight has more than 250 systems installed worldwide with users including BASF, BP, GlaxoSmithKline, Novartis, 3M Corp., Roche, Solvay and Unilever together with many universities and research institutes. There are currently 100+ third party papers citing NanoSight results, with this reference base growing very rapidly as NanoSight consolidates its key contribution to nanoparticle characterization.
Source: NanoSight (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
 
 
If you liked this article, please give it a quick review on reddit or StumbleUpon. Thanks!
 
 
These articles might interest you as well: